YZY is serious about drug R&D but its development progress is slow. There're many unanswered questions in the whole direction of BsAb. Either internally or externally, YZY has a long way to go.
Boomeranged on Tue, 5 Sep 2023 08:39
YZY passed the hearing of HKEX. We've analyzed its business, pipeline and concerns in this insight. It should be pointed out that investors have become very rational now, looking for companies with high certainty of commercialization performance and good cashflow - YZY is not qualified. Future valuation performance could hardly be satisfactory. Its valuation should be lower than Alphamab Oncology.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.